Opinion|Videos|March 19, 2025
Dr. Galsky’s Perspectives on Subcutaneous ICI Dosing
Author(s)Matthew Galsky, MD
An expert discusses how the availability of subcutaneous (SC) immune checkpoint inhibitors (ICI) for bladder cancer impacts treatment selection by offering improved convenience and accessibility, particularly in advanced/metastatic and perioperative settings. SC formulations may reduce costs, time, and patient burden while enhancing treatment compliance and follow-up.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How does availability of SC ICI impact treatment selection for your patients with bladder cancer? (NCCN 6.2024; Albiges 2025; Burotto 2024)
- In the advanced/metastatic setting
- In the perioperative setting
- From a practical standpoint, what potential cost and time savings could your center anticipate with SC ICI formulations?
- How might an SC option alleviate patient burden in treatment accessibility, compliance, and follow-up?
Advertisement
Related to this article
Oncologists weigh second-line options after IO/TKI failure in metastatic ccRCC, highlighting tolerability, mechanism shifts, and belzutifan’s broader role.
In the phase 3 EMBER-3 trial, imlunestrant plus abemaciclib doubled median progression-free survival vs imlunestrant alone in ESR1-mutated advanced breast cancer.
CELESTIMO trial shows mosunetuzumab plus lenalidomide boosts PFS in relapsed follicular lymphoma, supporting earlier-line outpatient, chemo-free care.
The FDA's Expedited Investigational New Drug (IND) Pilot Program pairs trial sponsors and research institutions to promote phase 1 trials in the US.
During a live event, Sikander Ailawadhi, MD, and participants considered a case patient with relapsed multiple myeloma after a quadruplet induction who declined CAR T-cell therapy.
FDA clears Triton 1 robotic colonoscopy for screening and advanced therapy, backed by first-in-human data showing high detection rates and reduced clinician workload.
Results from the phase 3 MAVERICK trial (SWOG S1827) show MRI surveillance alone improved cognitive failure-free survival vs adding PCI in SCLC.
The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Imlunestrant Plus Abemaciclib in ESR1-Mutated Breast Cancer
2
Data Increasingly Favor BCMA-Directed Therapy For Early-Relapse Myeloma
3
Sub-Q Amivantamab and Supportive Care Minimize Discontinuation in EGFR+ NSCLC
4
FDA Clears Robotic System for Endoscopic Procedures in the Colon
5